Skip to main
ABSI

Absci Corp (ABSI) Stock Forecast & Price Target

Absci Corp (ABSI) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Absci is a clinical-stage biotechnology company utilizing generative AI and high-throughput biology to develop novel protein therapeutics, notably ABS-201 (PRLR), currently in Phase 1/2a trials for Pattern Hair Loss (PHL). With promising preclinical data and a well-established market need for alternative treatments, Absci's approach may offer a differentiated and potentially more effective solution for a significant portion of the ~8-18% of women suffering from endometriosis. However, as with all early-stage biotech companies, there is no guarantee of success in the clinic.

Bears say

Absci is a biotechnology company that uses artificial intelligence and synthetic biology to develop novel biologic drugs for various diseases. However, the negative outlook is due to the competitive landscape and potential manufacturing risks associated with third-party suppliers. Additionally, there is uncertainty surrounding the company's ability to secure funding and successfully bring its candidates through clinical trials. While Absci has promising candidates, there is still a need for improvement in clinical outcomes and the company may face challenges in differentiating its products from existing treatments. Overall, there are various factors that could hinder Absci's success and negatively impact its stock.

Absci Corp (ABSI) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Absci Corp (ABSI) Forecast

Analysts have given Absci Corp (ABSI) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Absci Corp (ABSI) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Absci Corp (ABSI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.